Maxim Group Reaffirms Their Hold Rating on Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 272,850 shares of Nurix common ...
pharmaphorum23h
ViiV claims $1.25bn settlement from Gilead in HIV patent dispute
A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products.
Gilead got D'Arcy Carden
Dave Bautista recently commented on the possibility of his return as Drax the Destroyer in Guardians of the Galaxy 4 in the future. In 2023, Marvel Studios’ Guardians of the Galaxy 3 ended with the ...